Hansoh Pharmaceutical Group Co. Ltd.

11/05/2025 | Press release | Distributed by Public on 11/05/2025 01:29

圣罗莱®最新机制研究于《国际免疫药理学》发布，证实具有潜在心血管保护作用

1.Zhang X, Li S, Lin T,et al.Pegmolesatide ameliorates indoxyl sulfate-induced cardiomyocyte hypertrophy through modulating the EPOR-CD131-dependent JAK2/STAT3 signaling pathway.Int Immunopharmacol. 2025 Oct 14;167:115643.

2.Xie J, Yang A, Qiu H,et al. Randomized Trial of Pegmolesatide for the Treatment of Anemia in Patients With Nondialysis CKD.Kidney Int Rep. 2024 Dec 6;10(3):720-729.

3.Zhang P, Jiang Y, Xu C,et al.Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial.EClinicalMedicine. 2023 Oct 28;65:102273.

Hansoh Pharmaceutical Group Co. Ltd. published this content on November 05, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 05, 2025 at 07:29 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]